Oncology
Cancer clinical trials
Studies of cancers and tumors of every type and site, from prevention to treatment. We’re tracking 20,577 recruiting studies in this area right now.
By phase
- Not applicable9,767
- Phase 24,442
- Phase 12,740
- Phase 1/Phase 21,691
- Phase 31,394
- Phase 2/Phase 3281
- Phase 4262
Top conditions
- Breast Cancer1,226
- Cancer660
- Prostate Cancer651
- Colorectal Cancer495
- Lung Cancer424
- Ovarian Cancer340
- Multiple Myeloma334
- Gastric Cancer297
- Pancreatic Cancer294
- Acute Myeloid Leukemia291
- Hepatocellular Carcinoma283
- Solid Tumor256
- Advanced Solid Tumor255
- Cervical Cancer232
- Head and Neck Cancer224
- Endometrial Cancer206
- Advanced Solid Tumors192
- Bladder Cancer191
Leading sponsors
- M.D. Anderson Cancer Center450
- Fudan University311
- Sun Yat-sen University289
- Memorial Sloan Kettering Cancer Center288
- National Cancer Institute (NCI)286
- Mayo Clinic242
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences151
- City of Hope Medical Center146
- AstraZeneca132
- University Health Network, Toronto125
Where studies are running
- California1,421
- Texas637
- Arizona513
- Florida447
- Alabama420
- New York409
- Massachusetts342
- Maryland329
- New Jersey267
- Pennsylvania246
Recruiting studies20,577 total
- NCT06780111RecruitingPhase 1/Phase 2
Combination therapy study for advanced esophageal cancer
This trial tests new drug combinations for people with advanced squamous cell cancer of the esophagus that hasn't been treated yet. It aims to see if these combinations can shrink tumors and help patients live longer.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT07405151RecruitingPhase 1/Phase 2
New drug for advanced esophageal cancer after other treatments
This trial tests a new drug called Ifinatamab Deruxtecan for people with advanced esophageal squamous cell carcinoma that has progressed after one or two prior treatments. It aims to see if the drug can shrink tumors or slow the disease.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT06513962RecruitingPhase 3
Triptorelin to protect ovaries in young women with cancer
This study tests whether a medicine called triptorelin can protect the ovaries in young women and teens receiving strong chemotherapy for cancer. If you are newly diagnosed with a cancer (other than breast cancer) and are about to get certain chemotherapy drugs, this trial may help preserve your fertility.
Birmingham, AlabamaAges Up to 39 years - NCT07524218Recruiting
Meal Timing During Cancer Treatment Recovery
This study looks at how the timing of meals during cancer treatment recovery affects how well you tolerate and respond to your therapy. Researchers want to learn whether eating during certain hours of the day might help your body handle chemotherapy, targeted drugs, or immunotherapy better.
Los Angeles, CaliforniaAges 18 years+ - NCT05948813RecruitingPhase 2
TY-9591 for EGFR-mutant lung cancer spread to the brain
This phase 2 trial studies TY-9591 in people with advanced non-small cell lung cancer (NSCLC) that has spread to the brain and has specific EGFR mutations. It aims to see whether the medicine can control the cancer in the brain and the rest of the body, without needing immediate brain radiation.
Beijing, Beijing MunicipalityAges 18–80 - NCT04684368RecruitingPhase 2
New treatment study for children and young adults with NGGCT brain tumors
This Phase 2 study tests a new treatment approach for certain brain tumors called NGGCT in children and young adults. It may help improve outcomes by targeting tumors in specific brain locations and using tumor marker tests to guide care.
Birmingham, AlabamaAges 3–29 - NCT06619587RecruitingPhase 1
Study of GDC-7035 for advanced solid tumors with KRAS G12D
This trial tests a new oral drug (GDC-7035) for people with advanced solid tumors that have a specific KRAS mutation (G12D). The drug may be given alone or with other treatments to see if it is safe and helps fight the cancer.
La Jolla, CaliforniaAges 18 years+ - NCT07594626RecruitingPhase 1/Phase 2
BMS-986504 and Pemetrexed for Advanced Tumors With MTAP Loss
This trial tests a new drug (BMS-986504) combined with an existing chemotherapy (pemetrexed) for advanced solid cancers that have a specific genetic change called MTAP deletion. The trial aims to see if this combination can slow or stop tumor growth in patients whose cancer has progressed despite prior treatment.
Chicago, IllinoisAges 18 years+ - NCT07689864Recruiting
Unify: A study collecting fluid samples at Yale
This trial collects blood and possibly other fluid samples from people with cancer or those at high risk for cancer. The samples are stored for future research to better understand cancer.
New Haven, ConnecticutAges 18 years+ - NCT07784309Enrolling by invitationPhase 1
Cell therapy for CD7-positive blood cancer
This study tests a new cell therapy for people with certain types of blood cancer that have returned or not responded to standard treatments. The therapy uses immune cells modified to target a marker called CD7 on cancer cells. It may help reduce or eliminate the cancer.
TianjinAges 3–70 - NCT05235165RecruitingPhase 3
Surgery choice for lung spread of osteosarcoma
This Phase 3 trial compares two ways to remove lung metastases (open surgery vs keyhole surgery) in people with osteosarcoma. It aims to see which approach works better and is safer for patients with a limited number of lung spots that can be removed.
Birmingham, AlabamaAges Up to 50 years - NCT00006518Recruiting
Tissue samples from people with viral infections or cancer
This study collects tissue and blood samples from people who have or have been exposed to certain viruses (HIV, KSHV, HPV, EBV, or HTLV-1) or who have developed cancer or precancerous skin lesions. The samples help researchers understand how these viruses may lead to cancer.
Bethesda, MarylandAges 18–120 - NCT07466316RecruitingPhase 3
Comparing chemo schedules for intermediate-risk rhabdomyosarcoma
This trial compares two different chemotherapy schedules for children and young adults with intermediate-risk rhabdomyosarcoma (a type of muscle cancer). One group gets a higher dose of chemotherapy over a shorter period, while the other gets a lower dose plus maintenance therapy for a longer time. The goal is to see which approach works better.
Birmingham, AlabamaAges Up to 50 years - NCT05382338RecruitingPhase 3
Sodium thiosulfate to protect hearing in medulloblastoma
This Phase 3 study tests whether adding sodium thiosulfate during treatment for newly diagnosed medulloblastoma can reduce the risk of hearing loss. It is designed for children and teens whose cancer meets specific low-risk or average-risk tumor and lab features.
Birmingham, AlabamaAges 4–21 - NCT06672146RecruitingPhase 2
New treatments for AML with an IDH2 mutation
This trial tests new treatments for people with newly diagnosed acute myeloid leukemia (AML) that has a change in the IDH2 gene. It aims to find a better option for those who cannot have standard high-dose chemotherapy.
Tucson, ArizonaAges 18 years+ - NCT07488923RecruitingPhase 1
ML261 CAR T therapy for advanced small cell lung cancer and related neuroendocrine cancers
This trial tests a new treatment called ML261, which uses your own immune cells (T cells) that have been modified to target DLL3, a protein found on certain cancer cells. It is for people with advanced small cell lung cancer or other neuroendocrine cancers that have not responded to standard treatments.
St Louis, MissouriAges 18 years+ - NCT07681882RecruitingPhase 1
Testing DS1025a in people with advanced solid tumors
This trial tests a new drug, DS1025a, for people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if it is safe and how well it works.
KashiwaAges 18 years+ - NCT03126916RecruitingPhase 3
Testing added therapy for high-risk neuroblastoma in children
This Phase 3 study tests whether adding either a targeted drug (lorlatinib) or a radioactive treatment (131I-MIBG) to intensive chemotherapy improves outcomes for children with high-risk neuroblastoma. It may help by aiming at tumor cells more directly alongside standard treatment.
Birmingham, AlabamaAges 12 months–30 years - NCT06536049RecruitingPhase 1/Phase 2
Epcoritamab plus ibrutinib for relapsed or refractory aggressive B-cell lymphoma
This trial tests a combination of two drugs – epcoritamab (a type of immunotherapy that helps your immune system attack lymphoma cells) and ibrutinib (a targeted pill that blocks signals that help cancer grow). It is for people with aggressive B-cell lymphoma that has come back or not responded to at least 2 prior treatments.
Minneapolis, MinnesotaAges 18 years+ - NCT07227311RecruitingPhase 2
Belantamab mafodotin combinations for relapsed multiple myeloma
This trial tests a new drug called belantamab mafodotin (a targeted antibody therapy) combined with standard treatments for multiple myeloma that has come back or stopped responding. It looks at three different drug combinations to see which works best for people who have had 1 or 2 prior treatments.
Los Alamitos, CaliforniaAges 18 years+ - NCT07600801Recruiting
Lung Cancer Screening for People With Family History
This study looks at how to best screen people for lung cancer who have close relatives with a history of lung cancer. Researchers will use existing CT chest scans (imaging tests) to see if screening can help catch lung cancer early in high-risk families.
Boston, MassachusettsAges 18 years+ - NCT06342453Recruiting
Art therapy for children with cancer
This study tests whether art activities can help children with cancer cope and feel better. Kids will take part in four creative art sessions while receiving treatment.
Portland, OregonAges 8–13 - NCT05304585RecruitingPhase 3
Chemo for children with early, low-risk fusion-negative rhabdomyosarcoma
This Phase 3 study tests a chemotherapy plan for children and teens with newly diagnosed, very low-risk or low-risk rhabdomyosarcoma that does not have certain gene fusions (FOXO1 fusion negative). The goal is to see if this treatment can work well while limiting side effects by matching therapy to early-stage risk.
Birmingham, AlabamaAges Up to 21 years - NCT06975293RecruitingPhase 1/Phase 2
STC-15 with toripalimab for advanced cancers and sarcomas
This trial tests a new drug called STC-15, either alone or with another drug (toripalimab), for people with certain advanced cancers or sarcomas that have progressed after prior treatment. The goal is to see if this combination or single drug can help shrink tumors or slow the disease.
San Francisco, CaliforniaAges 18 years+
Common questions
- How many cancer clinical trials are recruiting?
- Clin2 is tracking 20,577 recruiting oncology studies from the U.S. registry right now, out of 31,031 we cover in this area in total.
- What does “Cancer” cover here?
- Studies of cancers and tumors of every type and site, from prevention to treatment. We group each study into cancer based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a cancer trial near me?
- Use the search to filter cancer studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
- Brain & nervous system
- Heart & circulation
- Hormones & metabolism
- Mental health
- Digestive system
- Lungs & breathing
- Immune system & allergy
- Women’s health & pregnancy
- Skin
- Blood & lymphatic
- Kidney & urinary
- Infections
- Genetic & congenital
- Bones, joints & muscles
- Pain
- Injuries & trauma
- Mouth & dental
- Eyes & vision
- Ear, nose & throat
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.